

JIA HU

████████████████████ • Calgary, AB, Canada • ██████████
████████████████████ • ██████████

EDUCATION:

- 2017 **University of Toronto** (*Toronto, Canada*)
Specialist training in Public Health and Preventive Medicine
- 2015 **London School of Economics & London School of Hygiene & Tropical Medicine** (*London, UK*)
Masters in Health Policy, Planning, and Finance
- 2014 **University of Toronto & St. Michael's Hospital** (*Toronto, Canada*)
Clinical training in family medicine with a focus on marginalized patients (HIV, homeless, refugees)
- 2012 **University of Alberta** (*Edmonton, Canada*)
Doctor of Medicine | Awarded Dean's Citation - highest entrance scholarship
- 2007 **Harvard University** (*Cambridge, USA*)
Honors Bachelor of Arts in Economics, focus on development economics (transferred from University of Alberta in 2005)

NON-CLINICAL WORK EXPERIENCE:

- Aug 20-present **Chair and co-founder, 19 To Zero** (*Calgary, Canada*)
- 19 To Zero is a 500+ person coalition of public health, academia, government officials, civil society organizations, and private sector partners with a primary focus on COVID-19 behaviour change and vaccine uptake
 - Lead efforts around healthcare worker education and engagement; community outreach, large-scale data-driven marketing campaigns, and comprehensive social media analysis and interventions
 - Within Canada, work with dozens of organizations like PHAC, Ontario Ministry of Health, AHS/AH, regional/local health authorities, municipalities, to support COVID-19 work
 - On the research side, lead a team of 10+ principal investigators with expertise in public health, behavioural economics, vaccinology, machine learning, etc. across Canada, the United States, and globally to generate the data to inform interventions
 - Lead global vaccine confidence work in my role as head of CONVINCENCE (<https://www.vaccineconfidence.org/convince>) Canada alongside Dr Heidi Larson from LSHTM and Dr Scott Ratzan from CUNY with dozens of partners like the WHO, UN, national CDCs and public health agencies, and civil society organizations
- Feb 20-present **Corporate Medical Director, Canadian Pension Plan Investments** (*Toronto, Canada*)
- Providing advice on a wide range of health issues to improve employee health & wellness, with a focus on COVID-19 preparedness and response
 - This role is through Cleveland Clinic Canada's Strategic Advisory Practice, so I have supported other clients including Air Canada, Purolator, Shoppers Drug Mart, retail banks (TD, Scotiabank, BMO, etc.), etc.
- Sep 18-May 21 **Medical Officer of Health, Alberta Health Services (AHS)** (*Calgary, Canada*)
- Helping lead Calgary Zone and Alberta's COVID response – with highlights including:

- Coordinated the development of the COVID Care Pathway (that enabled family doctors to follow-up with all COVID+ patients)
- Led the Cargill outbreak response, including rapidly coordinating work between public health, all primary care in Calgary Zone, and newcomer organizations to respond urgently to the health and socioeconomic needs of affected workers
- Increased contact tracing capacity 8-fold in three weeks by training medical students
- Worked with University of Calgary Dean's Task Force to support COVID, with initiatives including local production of PPE, deployment of nursing & social work students to COVID response, etc.
- Led the AHS rollout of North America's first contact tracing app
- Prior to COVID, responsible for communicable disease control and immunization-related issues (case and outbreak management, operational improvement, policy development)

Jul 17-Sep 18 **Associate Consultant: McKinsey & Company** (*Toronto, Canada*)

- Conducted a due diligence on an antibiotics manufacturer, which involved estimating current and future rates of ESBL & CRE and modelling the potential addressable market of novel medicines targeting these diseases.
- Performed a strategic analysis for a large healthcare distributor (>\$100 billion in revenue) and identified value creation opportunities in terms of growth, cost reduction, and improved capital efficiency across its major business units.

May 17-Feb 17 **Consultant (part-time): Public Health Agency of Canada** (*Ottawa, Canada*)

- Drafted immunogenicity recommendations for Shingrix (novel zoster vaccine) used to inform national guidelines on its use and administration.

Oct 14-Aug 17 **Policy consultant (part-time): London School of Economics Enterprise** (*London, UK*)

- Led a team of six to write an overview of Chinese pharmaceutical policy along with reform recommendations, a document commissioned by China's State Council.
- Consulted on health systems reform, particularly in healthcare financing, for various national governments.

CLINICAL WORK EXPERIENCE:

Jul 14-present **Physician, East Edmonton Family Care Centre and Medicentres Canada** (*Edmonton & Calgary, Canada*)

- Providing full-scope family practice in both a walk-in clinic setting as well as at an inner city clinic for patients with complex medical, mental health, and substance abuse issues.

Mar 19-present **Long-Term Care Physician, Rouleau Manor** (*Calgary, Canada*)

- Cared for a population of long-term care residents on a locked dementia unit; patients have significant mental health and behavioral issues.

Jul 14-Aug 16 **Hospitalist Staff Physician (part-time): Peter Lougheed Hospital** (*Calgary, Canada*)

- Collaborated with allied health and physicians along with patients and their families to provide high quality patient-centered care from admission through to discharge.

LEADERSHIP EXPERIENCE:

May 19-present **Board Member, Partners in Health (PIH) Canada** (*Toronto, Canada*)

- PIH is a global health charity headquartered in Boston with a focus on health systems strengthening in developing countries.
- Working with the executive director to diversify funding and develop a strategic plan to increase PIH Canada activities both internationally and with Indigenous populations domestically.

- May 19-present **Treasurer and Exec Member: Public Health Physicians of Canada (PHPC)** (*Ottawa, Canada*)
- Providing financial oversight to PHPC, the national specialist society for public health physicians.
 - Worked with leadership team to significantly increase membership and revenues through a partnership with Quebec physicians.
 - Drafting public health specialist society recommendations for Choosing Wisely Canada campaign.
- 2016-present **Board Member, Canadian Spondylitis Association** (*Toronto, Canada*)
- CSA is the primary patient advocacy and support groups for people living with ankylosing spondylitis and other spondylo-arthropathies.
 - Helped resolve significant dysfunction between the executive director and the President through development of more formalized governance and accountability mechanisms.
 - Developed strategic plan in conjunction with the board with a focus on increasing professionalism and funding diversity for the organizations.

GRANTS & OTHER FUNDING

2020

Assessing and Changing Attitudes Towards COVID-19 Vaccine Through Targeted Marketing, Nudging, and Community Outreach

Principal Investigator: J Hu

Co-Investigators: Manns B, Oxoby R, Marshall D, Boucher JC, Lang R, Benham J, Tang T, Fullerton M, and others

Funding Source: \$529,638 from Alberta Innovates and Pfizer Alberta Collaboration in Health Fund

2020

Obstacles and Nudges to Ameliorate Contact Tracing with ABTraceTogether App (CONTACT-APP)

Principle Investigator: J Hu

Co-applicants: Braden Manns, Hasan Sheikh, Rob Oxoby, Mehdi Mourali, Deborah Marshall, Jamie Benham, Raynell Lang

Funding Source: \$50,000 from University of Calgary Clinical Research Fund

2020

Obstacles and Nudges to Ameliorate Contact Tracing with ABTraceTogether App (CONTACT-APP)

Principle Investigator: J Hu

Co-applicants: Braden Manns, Hasan Sheikh, Rob Oxoby, Mehdi Mourali, Deborah Marshall, Jamie Benham, Raynell Lang

Funding Source: \$392,769 from Alberta Innovates

2020

Intergenerational Needs Assessment of COVID-19 Behaviour and Vaccine Confidence Using Digital Marketing Platforms & Behavioral Economic Nudges

Principal Investigator: J Hu

Funding Source: \$40,000 from GlaxoSmithKline Canada

2020

Improving COVID-19 Behavior and Vaccine Confidence

Principal Investigator: J Hu

Funding Source: \$40,000 from Sanofi Canada

2020

Intergenerational Assessments of Vaccine Behaviour and Confidence Using Healthy Education Campaigns & Behavioral Economic Nudges

Principal Investigator: J Hu

Funding Source: \$40,000 from Merck Canada Inc.

2020

National Vaccine Confidence Campaign

Principal Investigator: J Hu

Fund Source: \$200,000 from Suncor Energy

2020

National multi-modal vaccine hesitancy behaviour-change campaign and Community Engagement

Principal Investigator: J Hu

Fund Source: \$200,000 from Loblaw/Shoppers Drug Mart

2020

Promoting Safe COVID-19 Behaviours in the Community

Principal Investigator: J Hu

Co-applicants: Jamie Benham, Franco Rizzuti

Fund Source: \$3,000 from Alberta Medical Association

2020

Building Confidence in Pharmacy-Delivered Vaccines

Principal Investigator: J Hu

Fund Source: \$175,000 from GlaxoSmithKline Canada

2020

Building Confidence in COVID-19 Vaccines Amongst Low-Income Essential Worker Communities

Principal Investigator: J Hu

Fund Source: \$200,000 from Moderna Canada

2020

Understanding current vaccination barriers to demonstrate the importance of pharmacies in future vaccine programs

Principal Investigator: J Hu

Fund Source: \$40,000 from Neighbourhood Pharmacy Association of Canada

2020

COVID-19: Utilizing smart phone sensors and activity trackers for remote vitals monitoring and screening

Principle Investigators: J Shor

Principal Partner: J Hu

Co-applicants: D Krishamurthy, STM Wang

Funding Source: \$50,000 from NSERC Alliance Program

2020

Smart Cloud for COVID-10 Prevention and Control

Principle Investigators: STM Wang

Principal Partner: J Hu

Co-applicants: D Krishamurthy, J Wang

Funding Source: \$50,000 from NSERC Alliance Program

2020

Wastewater surveillance of SARS-CoV2 to enable real-time clinical case finding in Calgary

Principle Investigators: M Parkins, C Hubert

Co-applicants: **J Hu**, G Achari, J Cabaj, J Conly, J Meddings, C Naugler, D Pillai, N Rucker, C Ryan

Funding Source: \$505,310 from CIHR

2020

The Anatomy, Determinants, and Impacts of the Cargill COVID-19 Outbreak Among Newcomers and their Families in Canada

Principle Investigators: G Fabreau, K Pottie

Knowledge Users: **J Hu**, D Hinshaw, B Friesen, et al.

Funding Source: \$365,000 from CIHR

2020

Policy Implementation and Communication Lessons from Alberta's Acute and Primary Care Environments during the COVID-19 Response

Principle Investigators: M Leslie, J Conly

Co-Investigators: **J Hu**, R Fadaak, O Larios, N Lee, R Schindler, J Seidel, G Tipples

Funding: \$429,646 from CIHR COVID-19 Rapid Response Operating Grant

2020

2020-2022

Development and implementation of rapid metagenomic sequencing coupled with isothermal amplification point of care testing for viral diagnostics

Principal Investigators: Pillai DR Chiu CY, Berenger G

Co-Investigators: **Hu J**, Berenger B

Funding Source: \$957,000 from CIHR and Genome Alberta

2020-2022

Alberta Childhood COVID-19 Cohort (AB3C) Study

Principal Investigators: F Bernier, JD Kellner. Co-Investigators: **J Hu**, M Esser, G Thompson, M Fritzler, M Croxen, N Forkert, S Benseler, B Berenger, J Blackwood, D Bulman, J Cabaj, A Eaton, E Castillo, C Constantinescu, W Dean, S Freedman, P Gordon, B Hallgrímsson, F Jirik, P Kannu, S Kuhn, T Lacaze, R Lamont, Q Long, D Marshall, A Melin, R Newton, J Parboosingh, R Pon, J Robinson, S Taylor, M Twilt, G Vomiero, O Vanderkooi, G van Marle, E Wang.

Funding: **\$577,500**, with **\$237,500** from Genome Alberta COVID-19 Rapid Response Program Competition and remainder from intramural matching (Alberta Children's Hospital Research Institute, Mitogen).

2019-2022

CASPER-PCV (Calgary Area *Streptococcus pneumoniae* Epidemiology Research-Pneumococcal Conjugate Vaccine) Study VI Extension – Surveillance and Analysis of Invasive Pneumococcal Disease (IPD), Pneumococcal Related Disease (PRD) and Nasopharyngeal (NP) Colonization in Canada.

Investigators: JD Kellner, OG Vanderkooi, **J Hu**.

Funding: **\$787,004**. Pfizer Pharmaceuticals (Investigator Initiated Research).

2017-2021

Canadian Immunization Research Network.

Principal Investigators: SA Halperin and 20 others. **J Hu** (Co-Investigator, with 108 others).

Funding: \$10,083,333. CIHR and Public Health Agency of Canada.

2018-2020

A Randomized Controlled Trial to Compare a 1-Dose vs 2-Dose Priming Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Canadian Infants.

Principal Investigators: M Sadarangani, OG Vanderkooi. Co-Investigators: **J Hu**, JD Kellner, C Quach, J Langley, J MacDonald

Funding: **99,035.00**. Alberta Children's Hospital Research Institute \$50,000.00 & Canadian Immunization Research Network \$49,035.00)

2018-2020

A Randomized Controlled Trial to Compare Protection in Adolescents Between Different Meningococcal Immunization Schedules Used in Canada.

Principal Investigators: M Sadarangani, OG Vanderkooi. Co-Investigators: J Bettinger, **J Hu**, JD Kellner, J Langley, J Alcantara, J MacDonald, M Naus.

Funding: **98,674.50**. Alberta Children's Hospital Research Institute \$50,000.00 & Canadian Immunization Research Network \$48,674.50)

2019 – 2020

A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator- controlled Study to Evaluate the Safety and Tolerability of V114-031 in Healthy Infants (PNEU – LINK, ClinicalTrials.gov Identifier: NCT03692871).

Investigators: Kellner JD (Site Principal Investigator), **Hu J**, Constantinescu C, Vanderkooi OG.

Funding: **\$345,045** Merck & Company (Contract).

2019 – 2021

A Phase III, Observer-Blind, Randomized, Multicountry Study to Assess the Reactogenicity and Safety of the Porcine Circovirus (PCV) Free Liquid Formulation of GSK's Oral Live Attenuated Human Rotavirus (HRV) Vaccine as Compared to the Lyophilized Formulation of the GSK's HRV Vaccine, When Administered as a 2-Dose Vaccination in Infants Starting at Age 6-12 Weeks (208236 ROTA-096, ClinicalTrials.gov Identifier: NCT03954743).

Investigators: Kellner JD (Site Principal Investigator), **Hu J**, Constantinescu C, Vanderkooi OG.

Funding: **\$120,770** GlaxoSmithKline Canada (Contract).

SELECTED PUBLICATIONS & ABSTRACTS:

1. Benham JL, Lang R, Kovacs Burns K, MacKean G, Léveillé T, McCormack B, Sheikh H, Fullerton MM, Tang T, Boucher JC, Constantinescu C, Mourali M, Oxoby RJ, Manns BJ, **Hu J**, Marshall DA. Attitudes, current behaviours and barriers to public health measures that reduce COVID-19 transmission: A qualitative study to inform public health messaging. PLoS ONE. 2021. 16(2): e0246941. <https://doi.org/10.1371/journal.pone.0246941>

2. Lang R, Benham JL, Atabati O, Hollis A, Tombe T, Shaffer B, Kovacs Burns K, MacKean G, Léveillé T, McCormack B, Sheikh H, Fullerton MM, Tang T, Boucher JC, Constantinescu C, Mourali M, Manns BJ, Marshall DA, **Hu J**, Oxoby RJ. Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging. *BMC Public Health*. 2021. 21, 765. <https://doi.org/10.1186/s12889-021-10790-0>
3. Berenger BM, Conly JM, Fonseca K, **Hu J**, Louie T, Schneider AR, Singh T, Stokes W, Ward L, Zelyas N. Saliva collected in universal transport media is an effective, simple and high-volume amenable method to detect SARS-CoV-2. *Clinical Microbiology and Infection*. 2021 Apr 1;27(4):656-7.
4. Kanji JN, Zelyas N, MacDonald C, Pabbaraju K, Khan MN, Prasad A, **Hu J**, Diggle M, Berenger BM, Tipples G. False negative rate of COVID-19 PCR testing: a discordant testing analysis. *Virology journal*. 2021 Dec;18(1):1-6.
5. Stokes W, Berenger BM, Portnoy D, Scott B, Szelewicki J, Singh T, Venner AA, Turnbull L, Pabbaraju K, Shokoples S, Wong AA, Gill K, Guttridge T, Proctor D, **Hu J**, Tipples G. Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19. *European Journal of Clinical Microbiology & Infectious Diseases*. 2021 Mar 20:1-6.
6. Pang JX, Singh J, Freedman SB, Xie J, **Hu J**. Improving follow-up testing in children with Shiga toxin-producing *Escherichia coli* through provision of a provider information sheet. *Australian Journal of Primary Health*. 2021 Jan 11;26(6):479-83.
7. Acosta N, Bautista M, Hollman J, McC Calder J, Beaudet AB, Man L, Waddell BJ, Chen J, Li C, Kuzma D, Bhatnagar S, Leal J, Meddings J, **Hu J**, Cabaj JL, Ruecker NJ, Naugler C, Pillai DR, Achari G, Ryan C, Conly JM, Frankowski K, Hubert CRJ, Parkins MD. Wastewater Monitoring of SARS-CoV-2 from Acute Care Hospitals Identifies Nosocomial Transmission and Outbreaks. *medRxiv*. 2021 Jan 1.
8. Acosta N, Bautista MA, Hollman J, McC Calder J, Beaudet AB, Man L, Waddell BJ, Chen J, Li C, Kuzma D, Bhatnagar S... **Hu J**. et al. A Multicenter Study Investigating SARS-CoV-2 in Tertiary-Care Hospital Wastewater. Viral burden correlates with increasing hospitalized cases as well as hospital-associated transmissions and outbreaks. *Water Research*. 2021 Jun 17:117369.
9. Burak KW, Law S, Rice C, **Hu J**, Fung CI, Woo AK, Fonseca K, Lang AL, Kanji JN, Meatherall BL. COVID-19 outbreak among physicians at a Canadian curling bonspiel: a descriptive observational study. *CMAJ open*. 2021 Jan;9(1):E87.
10. Lin YC, Malott RJ, Ward L, Kiplagat L, Pabbaraju K, Gill K, Berenger BM, **Hu J**, Fonseca K, Noyce R, Louie T. Detection and Quantification of Infectious Severe Acute Respiratory Coronavirus-2 in Diverse Clinical and Environmental Samples from Infected Patients: Evidence to Support Respiratory Droplet, and Direct and Indirect Contact as Significant Modes of Transmission. *medRxiv*. 2021 Jan 1.
11. Stokes W, Berenger B, Singh T, Adeghe I, Schneider A, Portnoy D, King T, Scott B, Pabbaraju K, Shokoples S, Wong AA, Gill K, Turnbull LA, **Hu J**, Tipples G. Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19. *medRxiv*. 2020 Jan 1.
12. Fonn S, **Hu J**, Igumbor JO, Gatoto D, Muula A, Ezeh A. Quantifying the cost of in-kind contributions to a multidonor-funded health research capacity-building programme: the case of the Consortium for Advanced Research Training in Africa. *BMJ global health*. 2020 Jun 1;5(6):e002286.

13. Oberding L, **Hu J**, Berenger B, Mohon AN, Pillai DR. Quantification of SARS-CoV-2 viral copy number in saliva mouthwash samples using digital droplet PCR. medRxiv. 2020 Jan 1.
14. Berenger, BM, Fonseca K, Schneider AR, **Hu J**, Zelyas N. Sensitivity of Nasopharyngeal, Nasal and Throat Swab for the Detection of SARS-CoV-2. medRxiv. 2020. doi: <https://doi.org/10.1101/2020.05.05.20084889>
15. Charlton CL, Kanji JN, Johal K, Bailey A, Plitt SS, MacDonald C, Kunst A, Buss E, Burnes LE, Fonseca K, Berenger BM, Schnabi K, **Hu J**, Stokes W, Zelyas N, Tipples G. Evaluation of six commercial mid-to high-volume antibody and six point-of-care lateral flow assays for detection of SARS-CoV-2 antibodies. Journal of clinical microbiology. 2020 Sep 22;58(10):e01361-20.
16. Fonn S, **Hu J**, Igumbor JO et al. Quantifying the cost of in-kind contributions to a multidonor-funded health research capacity-building programme: the Case of the Consortium for Advanced Research Training in Africa. BMJ Global Health. 2020;5:e002286. doi:10.1136/bmjgh-2020-002286
17. Summers A, **Hu J**, Berger L. The important role of family physicians in reporting communicable diseases: An outbreak of Hepatitis A in a kindergarten class. Can Fam Physician. 2018 Oct; 64(10): 742–743.
18. Ozaldin O, Shulman L, Summers A, **Hu J**, Dubey V, Stuart R. Investigation and management of a large mumps outbreak among young adults in Toronto. The Ontario Public Health Convention. Toronto, Ontario, March 2018. Poster presentation.
19. **Hu J**, Tcholakov Y, Young E. Public Health Impacts of Free Trade Agreements. Canadian Public Health Association Conference. Halifax, Canada, June 2017. Oral presentation.
20. Chen CE, Chen CT, **Hu J**, Mehrotra A. Walk-in clinics versus primary care clinics and emergency rooms for low-acuity urgent care and chronic disease management. Cochrane Database Syst Rev. 2017 Feb 17;2:CD011774. doi: 10.1002/14651858.CD011774.pub2.
21. Contributing author. Cancer Care Ontario, Ontario Agency for Health Protection and Promotion (Public Health Ontario). Environmental Burden of Cancer in Ontario. Toronto: Queen’s Printer for Ontario; 2016.
22. Samji H, **Hu J**, Moore D, Hull M, Otterstatter M, Grennan T, Brownrigg B, Janjua N, Tyndall M, Ogilvie G, Wong J. HIV Incidence among MSM Attendees of Sexually Transmitted Infection Clinics across British Columbia, Canada. 20th International Workshop on HIV Observational Databases. Budapest, Hungary, 7th-9th April, 2016. Poster Presentation.
23. Mossialos E, Ge YF, **Hu J**, Wang LJ. Pharmaceutical Policy Reforms in China: Challenges and Opportunities for Reform. World Health Organization. 2016.
24. **Hu J**, Mossialos E. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. Health Policy. 2016 May; 120(5): 519-34.
25. Self JL, Kedera E, Grant F, Wamalwa M, **Hu J**, Low J, Cole D, Girard AW, Levin C. Financial costs of MAMA-SASHA – a project to improve health and nutrition through an integrated orange flesh sweet potato production and health service delivery model. The Journal of the Federation of American Societies for Experimental Biology. 2014 Apr: Volume 28, No. 1 supplement 132.6.
26. **Hu J**, Mansur RB, McIntyre RM. Mixed specifier for bipolar mania and depression: Highlights of changes in the DSM-5 and implications for diagnosis and treatment in primary care. Prim Care Companion CNS Disord. 2014;16(2). pii: PCC.13r01599. doi: 10.4088/PCC.13r01599. Epub 2014 Apr 17.

27. Ezekowitz JA, **Hu J**, Delgado D, et al. Acute heart failure: Perspectives from a randomized trial and a simultaneous registry. *Circulation – Heart Failure*. 2012 Nov;5(6):735-41
28. Lau D, **Hu J**, Majumdar SR, Storie DA, Rees SE, Johnson JA. Interventions for improving influenza and pneumococcal vaccination rates in community dwelling adults: Systematic review and meta-analysis. *Annals of Family Medicine*. 2012 Nov-Dec;10(6):538-46.
29. Forgie SE, Keenliside J, Wilkinson C, Webby R, Lu P, Sorensen O, Fonseca K, Barman S, Rubrum A, Stigger E, Marrie TJ, Marshal F, Spady D, **Hu J**, Loeb M, Russell ML, Babiuk LA. Human to swine transmission of pandemic influenza A (H1N1) on a Canadian Swine Farm. *Clinical Infectious Diseases*, 2011; 52(1):10-18.
30. Kurien G, **Hu J**, Harris J, Seikaly H. Cost Effectiveness of PET/CT in the management of advanced head and neck cancer. *Journal of Otolaryngology – Head and Neck Surgery*. 2011 Dec; 40(6):468-72.
31. **Hu J**, Doucette K, Hartling L, Tjosvold L, Robinson JL. Treatment of hepatitis C in children: A systematic review. *PLOS ONE*. 2010; 5: e11542. doi: 10.1371/journal.pone.0011542.
32. **Hu J**, Robinson JL. Systematic review of invasive Acinetobacter infections in children. *Canadian Journal of Infectious Diseases and Medical Microbiology*.2010; 21(2), 83-88.

ADDITIONAL SKILLS & INTERESTS:

- **Languages:** English (fluent); Chinese (able to speak and read fluently); French (beginner)
- **Computer skills:** Highly proficient at MS Word, Powerpoint, Excel; familiarity with STATA and ArcGIS
- **Interests:** Jogging (completed my first marathon in 2013); Trivia (auditioned for the American T.V. show 'Jeopardy' and British T.V. show 'University Challenge'); Squash (recreational player)